Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses

OBJECTIVE: Exposure‐response (E‐R) models were developed to provide a description of the time‐course of treatment effect for monthly and quarterly dosing regimens of fremanezumab. BACKGROUND: Fremanezumab is a monoclonal antibody for preventive treatment of episodic migraine (EM) and chronic migrain...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiedler‐Kelly, Jill, Passarell, Julie, Ludwig, Elizabeth, Levi, Micha, Cohen‐Barak, Orit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496732/
https://www.ncbi.nlm.nih.gov/pubmed/32445498
http://dx.doi.org/10.1111/head.13845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496732/
https://www.ncbi.nlm.nih.gov/pubmed/32445498
http://dx.doi.org/10.1111/head.13845

Ejemplares similares